Importantly, systemic delivery of ASO-10-27 in neonatal SMA mice enhanced SMN levels in peripheral tissues as well as in the central nervous system determining an increased skeletal muscle function and a significant rise in survival rate [110,111]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.